41 mins. ago
Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies' experimental Lyme disease vaccine candidate, and will now begin the official review.
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#disease
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#disease
2 hours ago
White House chief of staff Susie Wiles is "cancer free," she announced on X on Sept. 16, 2026. "Some personal news I'm grateful to share. After a medical appointment at the Mayo Clinic this week, my pathology results came back clear," she explained.
Wiles was diagnosed with early-stage breast cancer in March and told the New York Times that her prognosis was "strong." Wiles did not disclose at the time what treatment she would undergo, but said it would last several weeks — during which time she planned to continue working. Noting that one in eight American women develops breast cancer at some point in their lives, Wiles posted on X at the time: "Every day, these women continue to raise their families, go to work and serve their communities with strength and determination. I now join their ranks."
A breast cancer diagnosis is life-altering, but Wiles's comments highlighted the progress that's been made in recent years. Breast cancer is now detected at Stage 0 or 1 — before it has spread — in the majority of cases. Survival rates have risen dramatically, but "the treatments we use to treat early-stage breast cancer have become more tailored" and less disruptive to women's lives, Dr. Lynn Dengel, a University of Virginia surgical oncologist, told Yahoo in March.
"Because [Wiles] was taking care of her health [and getting screened], not only will her prognosis be better, but it will probably minimize what treatment she has to go through and will benefit her work-life and overall balance," Dengel said. She added that most of her patients are diagnosed early and can continue to work while undergoing breast cancer treatment, reducing the financial burden and overall disruption to their lives.
Wiles was diagnosed at age 68 — slightly older than the median age (62) when most women learn they have breast cancer. More than 380,000 American women are diagnosed with some form of breast cancer each year, according to the American Cancer Society (ACS).
Breast cancer remains the most common form of cancer among women in the U.S., except for skin cancers. And rates are rising. But there's good news: More women are surviving the disease. Treatments have also improved, becoming tolerable enough that many women still work, as Wiles intends to do. Here's what to know about the disease, why rates are rising and how women can reduce their risks.
#breast #diagnosed
Wiles was diagnosed with early-stage breast cancer in March and told the New York Times that her prognosis was "strong." Wiles did not disclose at the time what treatment she would undergo, but said it would last several weeks — during which time she planned to continue working. Noting that one in eight American women develops breast cancer at some point in their lives, Wiles posted on X at the time: "Every day, these women continue to raise their families, go to work and serve their communities with strength and determination. I now join their ranks."
A breast cancer diagnosis is life-altering, but Wiles's comments highlighted the progress that's been made in recent years. Breast cancer is now detected at Stage 0 or 1 — before it has spread — in the majority of cases. Survival rates have risen dramatically, but "the treatments we use to treat early-stage breast cancer have become more tailored" and less disruptive to women's lives, Dr. Lynn Dengel, a University of Virginia surgical oncologist, told Yahoo in March.
"Because [Wiles] was taking care of her health [and getting screened], not only will her prognosis be better, but it will probably minimize what treatment she has to go through and will benefit her work-life and overall balance," Dengel said. She added that most of her patients are diagnosed early and can continue to work while undergoing breast cancer treatment, reducing the financial burden and overall disruption to their lives.
Wiles was diagnosed at age 68 — slightly older than the median age (62) when most women learn they have breast cancer. More than 380,000 American women are diagnosed with some form of breast cancer each year, according to the American Cancer Society (ACS).
Breast cancer remains the most common form of cancer among women in the U.S., except for skin cancers. And rates are rising. But there's good news: More women are surviving the disease. Treatments have also improved, becoming tolerable enough that many women still work, as Wiles intends to do. Here's what to know about the disease, why rates are rising and how women can reduce their risks.
#breast #diagnosed
2 hours ago
BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ***** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.
#biontech #survival
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ***** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.
#biontech #survival
2 hours ago
Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S. patients starting oral weight-loss medicines, a notable early gain against Novo Nordisk's Wegovy pill. Reuters reports that Wegovy initially held roughly 90% of the oral market, making Lilly's rapid share capture an important sign that the oral GLP-1 market is becoming a two-player competition rather than a Novo-dominated segment. The broader U.S. obesity-drug market is expected to exceed $100 billion annually by 2030, with oral treatments potentially accounting for more than one-third of GLP-1 use.
The timing is strategically important for Lilly because Foundayo was only launched in the U.S. in April 2026. The drug starts at $149 per month for self-pay patients and can cost as little as $25 for eligible commercially insured patients, while Medicare beneficiaries can access it through the GLP-1 Bridge program at $50 per month. Lilly's SEC filing says Mounjaro and Zepbound already represented 65% of its revenue in the first six months of 2026, highlighting both the importance of the incretin franchise and the opportunity for Foundayo to broaden Lilly's cardiometabolic revenue base.
The strongest bullish implication is that Foundayo appears to be overcoming the biggest behavioral barrier in obesity treatment: patients' preference for an oral medicine over an injection. Capturing more than 30% of new oral patients only months after launch suggests Eli Lilly and Company (NYSE:LLY) is establishing meaningful competitive positioning before the oral GLP-1 market fully scales. Foundayo's formulation also has a practical advantage because it can be taken at any time of day without food or water restrictions, while Lilly's clinical data showed an average 27.3-pound, or 12.4%, weight reduction at the highest dose among patients who remained on treatment in ATTAIN-1.
The commercial opportunity could become considerably larger if Foundayo gains indications beyond obesity. Lilly reported that in the ACHIEVE-3 trial, Foundayo produced a 57.1% greater relative reduction in A1C and a 73.6% greater relative reduction in body weight compared with oral semaglutide 14 mg. Lilly submitted Foundayo for type 2 diabetes in the U.S., EU, and ***** an, potentially expanding the addressable market beyond weight management.
The early oral-market traction also complements Eli Lilly and Company (NYSE:LLY)'s existing injectable franchise rather than simply cannibalizing it. A Lilly trial found that patients switching from maximum-tolerated Wegovy to Foundayo maintained all but 0.9 kg of their previous weight loss after one year, while patients switching from maximum-dose Zepbound to Foundayo maintained all but 5.0 kg. That suggests Foundayo could serve as a maintenance or lower-burden treatment within Lilly's broader obesity portfolio, increasing lifetime value per patient rather than limiting the opportunity to new prescriptions.
#weight
The timing is strategically important for Lilly because Foundayo was only launched in the U.S. in April 2026. The drug starts at $149 per month for self-pay patients and can cost as little as $25 for eligible commercially insured patients, while Medicare beneficiaries can access it through the GLP-1 Bridge program at $50 per month. Lilly's SEC filing says Mounjaro and Zepbound already represented 65% of its revenue in the first six months of 2026, highlighting both the importance of the incretin franchise and the opportunity for Foundayo to broaden Lilly's cardiometabolic revenue base.
The strongest bullish implication is that Foundayo appears to be overcoming the biggest behavioral barrier in obesity treatment: patients' preference for an oral medicine over an injection. Capturing more than 30% of new oral patients only months after launch suggests Eli Lilly and Company (NYSE:LLY) is establishing meaningful competitive positioning before the oral GLP-1 market fully scales. Foundayo's formulation also has a practical advantage because it can be taken at any time of day without food or water restrictions, while Lilly's clinical data showed an average 27.3-pound, or 12.4%, weight reduction at the highest dose among patients who remained on treatment in ATTAIN-1.
The commercial opportunity could become considerably larger if Foundayo gains indications beyond obesity. Lilly reported that in the ACHIEVE-3 trial, Foundayo produced a 57.1% greater relative reduction in A1C and a 73.6% greater relative reduction in body weight compared with oral semaglutide 14 mg. Lilly submitted Foundayo for type 2 diabetes in the U.S., EU, and ***** an, potentially expanding the addressable market beyond weight management.
The early oral-market traction also complements Eli Lilly and Company (NYSE:LLY)'s existing injectable franchise rather than simply cannibalizing it. A Lilly trial found that patients switching from maximum-tolerated Wegovy to Foundayo maintained all but 0.9 kg of their previous weight loss after one year, while patients switching from maximum-dose Zepbound to Foundayo maintained all but 5.0 kg. That suggests Foundayo could serve as a maintenance or lower-burden treatment within Lilly's broader obesity portfolio, increasing lifetime value per patient rather than limiting the opportunity to new prescriptions.
#weight
2 hours ago
Novo Nordisk A/S (NYSE:NVO)'s decision to rebrand its day-to-day identity as "Novo" and launch a cultural reset is primarily a strategic response to the company's loss of momentum in the obesity-drug market, rather than a financial restructuring in itself. Reuters reports that the company is trying to regain competitiveness as pressure from Eli Lilly intensifies. The move comes as Novo prepares to unveil new strategic ambitions at its September 21 Capital Markets Day, making the cultural reset potentially important if it leads to faster decision-making, stronger commercial execution and a more aggressive R&D approach.
The underlying business still has substantial scale to protect. Novo generated DKK 309.1 billion of 2025 sales and DKK 127.7 billion of operating profit, while obesity-care sales rose 31% at constant exchange rates to DKK 82.3 billion. However, the company also spent around DKK 8 billion on its transformation in 2025, and its diabetes value-market share fell 3.6 percentage points to 30.1%. The reset therefore comes at a critical point: Novo remains the global obesity-market leader, with a 59.6% branded-volume share in 2025, but Lilly is rapidly narrowing the competitive gap.
A successful cultural reset could improve Novo Nordisk A/S (NYSE:NVO)'s execution at a time when the company needs to convert its scientific and commercial ***** ets into faster growth. Reuters reported that CEO Mike Doustdar is already seeking to accelerate R&D and streamline decision-making following investor concerns about the pipeline and competition from Lilly. If the reorganization reduces internal bureaucracy and improves the speed of clinical, regulatory and commercial decisions, it could help Novo extract more value from its existing obesity portfolio while advancing next-generation treatments before the semaglutide patent cliff expected early next decade.
The company also has ***** ets that give a cultural and operational reset something concrete to build around. Wegovy was available in 52 countries by the end of 2025, while the company's higher-dose Wegovy achieved 20.7% weight loss in Phase 3 studies and its oral Wegovy achieved 16.6% weight loss. More recently, Wegovy received approval in China for MASH, expanding its potential beyond weight management and cardiovascular benefits into another large metabolic-disease market. If Novo Nordisk A/S (NYSE:NVO) can combine these products with better execution, the reset could support higher patient volumes and extend the commercial life of its GLP-1 franchise, helping defend revenue and cash flow despite pricing pressure.
#cultural #company #lilly
The underlying business still has substantial scale to protect. Novo generated DKK 309.1 billion of 2025 sales and DKK 127.7 billion of operating profit, while obesity-care sales rose 31% at constant exchange rates to DKK 82.3 billion. However, the company also spent around DKK 8 billion on its transformation in 2025, and its diabetes value-market share fell 3.6 percentage points to 30.1%. The reset therefore comes at a critical point: Novo remains the global obesity-market leader, with a 59.6% branded-volume share in 2025, but Lilly is rapidly narrowing the competitive gap.
A successful cultural reset could improve Novo Nordisk A/S (NYSE:NVO)'s execution at a time when the company needs to convert its scientific and commercial ***** ets into faster growth. Reuters reported that CEO Mike Doustdar is already seeking to accelerate R&D and streamline decision-making following investor concerns about the pipeline and competition from Lilly. If the reorganization reduces internal bureaucracy and improves the speed of clinical, regulatory and commercial decisions, it could help Novo extract more value from its existing obesity portfolio while advancing next-generation treatments before the semaglutide patent cliff expected early next decade.
The company also has ***** ets that give a cultural and operational reset something concrete to build around. Wegovy was available in 52 countries by the end of 2025, while the company's higher-dose Wegovy achieved 20.7% weight loss in Phase 3 studies and its oral Wegovy achieved 16.6% weight loss. More recently, Wegovy received approval in China for MASH, expanding its potential beyond weight management and cardiovascular benefits into another large metabolic-disease market. If Novo Nordisk A/S (NYSE:NVO) can combine these products with better execution, the reset could support higher patient volumes and extend the commercial life of its GLP-1 franchise, helping defend revenue and cash flow despite pricing pressure.
#cultural #company #lilly
2 days ago
New York Knicks star Jalen Brunson is getting the star treatment again after making an Emmys appearance with a "Law and Order: SVU" star.
The NBA champion cannot get away from the spotlight after helping guide New York to success in 2026. Brunson and the Knicks won the team's first championship in over 53 years after beating the San Antonio Spurs.
Meanwhile, Brunson's attention for the evening is shifting to the Emmys alongside Mariska Hargitay of the "Law and Order" franchise. Hargitay is a well-known Knicks superfan and attended many games throughout the team's championship run.
The two have become good friends since Brunson's move to the Knicks in 2022. Now, they're appearing on primetime award shows together.
MORE: Sydney Sweeney claps back with subtle message after backlash for suggestive ad
#york
The NBA champion cannot get away from the spotlight after helping guide New York to success in 2026. Brunson and the Knicks won the team's first championship in over 53 years after beating the San Antonio Spurs.
Meanwhile, Brunson's attention for the evening is shifting to the Emmys alongside Mariska Hargitay of the "Law and Order" franchise. Hargitay is a well-known Knicks superfan and attended many games throughout the team's championship run.
The two have become good friends since Brunson's move to the Knicks in 2022. Now, they're appearing on primetime award shows together.
MORE: Sydney Sweeney claps back with subtle message after backlash for suggestive ad
#york
2 days ago
Interested in Johnson & Johnson? Here are five stocks we like better.
Johnson & Johnson raised its growth ambitions, forecasting 6.5% adjusted operational sales growth and 7.3% adjusted EPS growth in 2026, with revenue expected to surpass $100 billion. Executives see 2027 improving further and aim for double-digit growth by the end of the decade despite STELARA biosimilar competition.
The company plans to detail its long-term growth strategy at an enterprise review in December, highlighting new product launches, a pipeline that includes 12 proof-of-concept molecules in Phase III, and the durability of growth beyond 2030.
Capital spending is focused on Innovative Medicine and MedTech launches, including ICOTYDE, cancer treatments, and the OTTAVA robotic surgical system. J&J also expects continued momentum from its myeloma therapies, ICOTYDE's expanding coverage, and MedTech products, while using acquisitions mainly to support growth beyond the current decade.
5 Defensive Stocks to Watch as CPI and the Fed Put the Rally to the Test
#adjusted #interested
Johnson & Johnson raised its growth ambitions, forecasting 6.5% adjusted operational sales growth and 7.3% adjusted EPS growth in 2026, with revenue expected to surpass $100 billion. Executives see 2027 improving further and aim for double-digit growth by the end of the decade despite STELARA biosimilar competition.
The company plans to detail its long-term growth strategy at an enterprise review in December, highlighting new product launches, a pipeline that includes 12 proof-of-concept molecules in Phase III, and the durability of growth beyond 2030.
Capital spending is focused on Innovative Medicine and MedTech launches, including ICOTYDE, cancer treatments, and the OTTAVA robotic surgical system. J&J also expects continued momentum from its myeloma therapies, ICOTYDE's expanding coverage, and MedTech products, while using acquisitions mainly to support growth beyond the current decade.
5 Defensive Stocks to Watch as CPI and the Fed Put the Rally to the Test
#adjusted #interested
2 days ago
Ashley St. Clair, former girlfriend of billionaire Elon Musk and mother to one of his children, told Don Lemon she personally witnessed the billionaire using ketamine recreationally and taking psychedelic mushrooms as she opened up about his alleged drug use.
St. Clair, who shares son Romulus with the Tesla and ***** eX chief, made the claims during an interview with Lemon after the podcast host recalled questioning Musk about his acknowledged use of prescription ketamine.
Musk has previously said he was prescribed ketamine for depression, but St. Clair claimed the drug use she witnessed went beyond therapeutic treatment.
"I have family members who have had great success from ketamine or ayahuasca treatments with professionals. The way I saw him –" she said. "Yeah. There's there but that's not the way he was using it. At least from my observation."
Pressed on what she meant, St. Clair replied: "I saw him use it recreationally."
#musk #lemon #recreationally #drug
St. Clair, who shares son Romulus with the Tesla and ***** eX chief, made the claims during an interview with Lemon after the podcast host recalled questioning Musk about his acknowledged use of prescription ketamine.
Musk has previously said he was prescribed ketamine for depression, but St. Clair claimed the drug use she witnessed went beyond therapeutic treatment.
"I have family members who have had great success from ketamine or ayahuasca treatments with professionals. The way I saw him –" she said. "Yeah. There's there but that's not the way he was using it. At least from my observation."
Pressed on what she meant, St. Clair replied: "I saw him use it recreationally."
#musk #lemon #recreationally #drug
2 days ago
Argentina's state-controlled energy company YPF is close to signing several LNG sales agreements for its planned Argentina LNG project as it races toward a final investment decision later this year.
YPF CEO Horacio Marín said at the Gastech conference in Bangkok that the company expects to sign two or three LNG contracts covering between 0.5 million and 1.5 million tonnes per year each. YPF aims to have the agreements secured before partners make a final investment decision in November.
The $24-billion Argentina LNG development, backed by YPF, Italy's Eni and Abu Dhabi's XRG, is designed to turn the vast Vaca Muerta shale formation into a major source of LNG for international markets.
The initial development will feature two floating LNG facilities with combined capacity of 12 million tonnes per year, with potential expansion to 18 million tonnes. A dedicated 527-kilometer pipeline will transport gas from Vaca Muerta to the Atlantic coast in Río Negro province. YPF says the development will also include gas treatment and liquids infrastructure.
Eni and XRG each hold approximately 32% interests in the upstream blocks feeding the development, with YPF holding 36%.
#development #year #tonnes #muerta
YPF CEO Horacio Marín said at the Gastech conference in Bangkok that the company expects to sign two or three LNG contracts covering between 0.5 million and 1.5 million tonnes per year each. YPF aims to have the agreements secured before partners make a final investment decision in November.
The $24-billion Argentina LNG development, backed by YPF, Italy's Eni and Abu Dhabi's XRG, is designed to turn the vast Vaca Muerta shale formation into a major source of LNG for international markets.
The initial development will feature two floating LNG facilities with combined capacity of 12 million tonnes per year, with potential expansion to 18 million tonnes. A dedicated 527-kilometer pipeline will transport gas from Vaca Muerta to the Atlantic coast in Río Negro province. YPF says the development will also include gas treatment and liquids infrastructure.
Eni and XRG each hold approximately 32% interests in the upstream blocks feeding the development, with YPF holding 36%.
#development #year #tonnes #muerta
2 days ago
Patriots-Steelers Broadcast Crew Features Fascinating Family Connection originally appeared on NESN. Add NESN as a Preferred Source by clicking here.
The New England Patriots will receive CBS' top broadcast treatment for their Week 2 home opener against the Pittsburgh Steelers.
Jim Nantz will handle play-by-play alongside new lead ***** yst J.J. Watt, with Tracy Wolfson reporting from the sideline. The ***** ignment creates an especially compelling storyline because Watt will be ***** yzing a game featuring his younger brother, Steelers star T.J. Watt. CBS announced its Week 2 and Week 3 broadcasting ***** ignments Monday, according to The Athletic's Richard Deitsch. Deitsch noted that J.J. Watt remains on the network's No. 1 team, while longtime lead ***** yst Tony Romo was not included on the schedule.
The Patriots will host the Steelers on Sunday, Sept. 20, at 1 p.m. ET at Gillette Stadium. The game will air on CBS.
J.J. Watt will have to ***** yze one of the people he knows best. T.J. Watt remains the centerpiece of Pittsburgh's defense and one of the NFL's most disruptive pass rushers. His matchup with New England's offensive line could become one of the deciding factors in the game.
#lead
The New England Patriots will receive CBS' top broadcast treatment for their Week 2 home opener against the Pittsburgh Steelers.
Jim Nantz will handle play-by-play alongside new lead ***** yst J.J. Watt, with Tracy Wolfson reporting from the sideline. The ***** ignment creates an especially compelling storyline because Watt will be ***** yzing a game featuring his younger brother, Steelers star T.J. Watt. CBS announced its Week 2 and Week 3 broadcasting ***** ignments Monday, according to The Athletic's Richard Deitsch. Deitsch noted that J.J. Watt remains on the network's No. 1 team, while longtime lead ***** yst Tony Romo was not included on the schedule.
The Patriots will host the Steelers on Sunday, Sept. 20, at 1 p.m. ET at Gillette Stadium. The game will air on CBS.
J.J. Watt will have to ***** yze one of the people he knows best. T.J. Watt remains the centerpiece of Pittsburgh's defense and one of the NFL's most disruptive pass rushers. His matchup with New England's offensive line could become one of the deciding factors in the game.
#lead
2 days ago
Steven Kolb apologized for physically restraining PETA activists during the COS runway show at New York Fashion Week
The protesters disrupted the show to highlight animal cruelty in the wool industry, calling for brands to stop using wool
PETA criticized Kolb's actions, while an activist announced that the organization plans to file a police report
A fashion executive is apologizing for his reaction to protesters crashing a New York Fashion Week show.
While models were walking the runway for the COS fall-winter 2026 collection in the WSA building on Sunday, Sept. 13, a group of animal activists from People for the Ethical Treatment of Animals (PETA) emerged holding signs and shouting against supporting the brand owned by Swedish retailer H&M, CNN, The New York Times and The Business of Fashion reported.
#fashion #peta #activists #animal
The protesters disrupted the show to highlight animal cruelty in the wool industry, calling for brands to stop using wool
PETA criticized Kolb's actions, while an activist announced that the organization plans to file a police report
A fashion executive is apologizing for his reaction to protesters crashing a New York Fashion Week show.
While models were walking the runway for the COS fall-winter 2026 collection in the WSA building on Sunday, Sept. 13, a group of animal activists from People for the Ethical Treatment of Animals (PETA) emerged holding signs and shouting against supporting the brand owned by Swedish retailer H&M, CNN, The New York Times and The Business of Fashion reported.
#fashion #peta #activists #animal
2 days ago
Brandi Glanville's health battle sparked an unexpected Bravo reunion, with Housewives stepping up financially. Several former co-stars donated to her GoFundMe after years of unexplained medical problems.
The fundraiser aimed to cover treatment costs linked to multiple diagnoses affecting Glanville. She admitted asking for help felt humiliating, but her medical expenses had pushed her toward crowdfunding.
TMZ reported that Glanville's GoFundMe had raised about $7,000 toward its $28,000 goal. Kyle Richards contributed $500, while Claudia Jordan and longtime friend James Maas each donated $100. Camille Grammer, who starred alongside Glanville on The Real Housewives of Beverly Hills, gave $200. She also explained why she decided to contribute despite their complicated history.
"I remember when she sent me flowers when I had my hysterectomy for uterine cancer," Grammer told TMZ. "I wanted to return the favor, and I feel bad for what she's going through." The pair had clashed during Real Housewives Ultimate Girls Trip in Morocco. Grammer acknowledged they were not particularly close, yet she still wanted to help.
Gina Rodriguez, another longtime friend, created the fundraiser earlier that week. She said doctors had discovered a fungal ball in Glanville's face that required removal. Glanville later discussed the fundraiser through her Brandi Glanville Unfiltered podcast. She broke down while describing the financial pressure surrounding her treatment.
#glanville #housewives #brandi #donated
The fundraiser aimed to cover treatment costs linked to multiple diagnoses affecting Glanville. She admitted asking for help felt humiliating, but her medical expenses had pushed her toward crowdfunding.
TMZ reported that Glanville's GoFundMe had raised about $7,000 toward its $28,000 goal. Kyle Richards contributed $500, while Claudia Jordan and longtime friend James Maas each donated $100. Camille Grammer, who starred alongside Glanville on The Real Housewives of Beverly Hills, gave $200. She also explained why she decided to contribute despite their complicated history.
"I remember when she sent me flowers when I had my hysterectomy for uterine cancer," Grammer told TMZ. "I wanted to return the favor, and I feel bad for what she's going through." The pair had clashed during Real Housewives Ultimate Girls Trip in Morocco. Grammer acknowledged they were not particularly close, yet she still wanted to help.
Gina Rodriguez, another longtime friend, created the fundraiser earlier that week. She said doctors had discovered a fungal ball in Glanville's face that required removal. Glanville later discussed the fundraiser through her Brandi Glanville Unfiltered podcast. She broke down while describing the financial pressure surrounding her treatment.
#glanville #housewives #brandi #donated
2 days ago
A man has been arrested and charged over an ******* ault at the Celtic v Hearts ******* le decider at Celtic Park.
The game on 16 May saw scores of fans run onto the pitch in injury time, after Celtic scored a third goal that clinched a 3-1 win and the Premiership ******* le.
Trouble also occurred in Glasgow's Trongate area after the game, with two police officers seriously injured and three members of the public needing hospital treatment.
The 38-year-old man is due to appear at Glasgow Sheriff Court at a later date.
More than 30 other people have been arrested over the trouble in the Trongate, for a number of different offences.
#arrested #game #park
The game on 16 May saw scores of fans run onto the pitch in injury time, after Celtic scored a third goal that clinched a 3-1 win and the Premiership ******* le.
Trouble also occurred in Glasgow's Trongate area after the game, with two police officers seriously injured and three members of the public needing hospital treatment.
The 38-year-old man is due to appear at Glasgow Sheriff Court at a later date.
More than 30 other people have been arrested over the trouble in the Trongate, for a number of different offences.
#arrested #game #park
4 days ago
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise.
On September 3, Citigroup **** yst Geoff Meacham highlighted the strategic importance of the Crinetics acquisition, arguing it could diversify Vertex's business while complementing its existing cystic fibrosis franchise and newer businesses in renal disease, hematology, and pain.
Through the transaction, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) gains access to Palsonify (paltusotine), an oral treatment for acromegaly that has already received regulatory approval in Europe. Paltusotine is also in Phase 3 development for carcinoid syndrome **** ociated with neuroendocrine tumors.
Palsonify is particularly important because it provides an immediate commercial revenue opportunity, rather than requiring the company to wait several years for an entirely new drug to reach the market.
Early uptake of Palsonify has been encouraging, supported by expanding physician adoption and improving reimbursement coverage. If that momentum continues, the drug could become an important contributor to Vertex's revenue growth.
#palsonify
On September 3, Citigroup **** yst Geoff Meacham highlighted the strategic importance of the Crinetics acquisition, arguing it could diversify Vertex's business while complementing its existing cystic fibrosis franchise and newer businesses in renal disease, hematology, and pain.
Through the transaction, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) gains access to Palsonify (paltusotine), an oral treatment for acromegaly that has already received regulatory approval in Europe. Paltusotine is also in Phase 3 development for carcinoid syndrome **** ociated with neuroendocrine tumors.
Palsonify is particularly important because it provides an immediate commercial revenue opportunity, rather than requiring the company to wait several years for an entirely new drug to reach the market.
Early uptake of Palsonify has been encouraging, supported by expanding physician adoption and improving reimbursement coverage. If that momentum continues, the drug could become an important contributor to Vertex's revenue growth.
#palsonify
4 days ago
Exelixis (EXEL) stock dropped out of a buy zone Friday after the Food and Drug Administration delayed the potential approval of its new colon cancer treatment by three months. The combination includes Exelixis' zanzalintinib and Roche's (RHHBY) Tecentriq. William Blair ***** yst Andy Hsieh says it's unlikely the agency will outright reject the combo, which showed an overall survival benefit for…
#rhhby #tecentriq #william
#rhhby #tecentriq #william
4 days ago
Toward the end of the lightning round on September 8, when a caller inquired about AstraZeneca PLC (NYSE:AZN), Mad Money host Jim Cramer commented:
Alright, now, AstraZeneca reminds me of a company, it's not unlike Novartis. I'm a little nervous about it. It's been missing some of its trials. I don't think COPD is enough to change my mind… I am not going to put my money on AstraZeneca.
AstraZeneca PLC (NYSE:AZN) maintains a solid financial foundation supported by steady top-line growth and disciplined cost management. In its second-quarter report, the company generated total revenue of $15.38 billion, marking a 6.4% increase compared to the same period last year. Adjusted earnings per share reached $2.63, outperforming ****** yst consensus estimates.
The profitability was driven by strong global demand for core oncology and rare disease treatments, which successfully offset revenue headwinds from generic competition affecting older blockbusters like Farxiga and Brilinta. With a net margin hovering around 17.02% and management reiterating its full-year guidance for mid-to-high single-digit revenue growth along with low double-digit core EPS expansion, the core business continues to demonstrate commercial resilience.
The primary driver behind the skepticism could be based on tangible execution risks and regulatory hurdles that threaten AstraZeneca PLC's (NYSE:AZN) long-term top line. A significant blow to the rare disease division came when anselamimab failed to achieve statistical significance for the primary endpoint in the overall AL amyloidosis population in the Phase III CARES program, although AstraZeneca reported encouraging results in a prespecified subgroup of patients with kappa light-chain amyloidosis.
#management
Alright, now, AstraZeneca reminds me of a company, it's not unlike Novartis. I'm a little nervous about it. It's been missing some of its trials. I don't think COPD is enough to change my mind… I am not going to put my money on AstraZeneca.
AstraZeneca PLC (NYSE:AZN) maintains a solid financial foundation supported by steady top-line growth and disciplined cost management. In its second-quarter report, the company generated total revenue of $15.38 billion, marking a 6.4% increase compared to the same period last year. Adjusted earnings per share reached $2.63, outperforming ****** yst consensus estimates.
The profitability was driven by strong global demand for core oncology and rare disease treatments, which successfully offset revenue headwinds from generic competition affecting older blockbusters like Farxiga and Brilinta. With a net margin hovering around 17.02% and management reiterating its full-year guidance for mid-to-high single-digit revenue growth along with low double-digit core EPS expansion, the core business continues to demonstrate commercial resilience.
The primary driver behind the skepticism could be based on tangible execution risks and regulatory hurdles that threaten AstraZeneca PLC's (NYSE:AZN) long-term top line. A significant blow to the rare disease division came when anselamimab failed to achieve statistical significance for the primary endpoint in the overall AL amyloidosis population in the Phase III CARES program, although AstraZeneca reported encouraging results in a prespecified subgroup of patients with kappa light-chain amyloidosis.
#management
4 days ago
STUART, FLORIDA - SEPTEMBER 2: Tiger Woods leaves the Martin County Courthouse on September 2, 2026 in Stuart, Florida. Tiger Woods is expected to change his plea in the case over a DUI crash that occurred on March 27, 2026, on Jupiter Island in Martin County. (Photo by Saul Martinez/Getty Images) Getty
Tiger Woods and Vanessa Trump are each working through a serious personal crisis.
Woods recently accepted a five-year driving ban. He pleaded no contest to reckless driving charges tied to his DUI case.
Trump, meanwhile, is recovering from breast cancer treatment. On June 13, she shared the beginning of the second phase of care. She had spent four weeks recovering from surgery beforehand.
Despite the separate hardships, People says the couple's relationship has grown stronger.
#tiger
Tiger Woods and Vanessa Trump are each working through a serious personal crisis.
Woods recently accepted a five-year driving ban. He pleaded no contest to reckless driving charges tied to his DUI case.
Trump, meanwhile, is recovering from breast cancer treatment. On June 13, she shared the beginning of the second phase of care. She had spent four weeks recovering from surgery beforehand.
Despite the separate hardships, People says the couple's relationship has grown stronger.
#tiger
5 days ago
Nyxoah SA (NASDAQ:NYXH) announced the first patient implantation in BREATHE on September 7. The prospective, single-arm U.S. post-approval study will evaluate Genio hypoglossal-nerve stimulation in adults aged 22 or older with moderate to severe obstructive sleep apnea for whom standard-care treatments have failed, cannot be tolerated, or are unsuitable. Plans call for up to 229 patients at up to 25 centers, with follow-up lasting up to five years.
For Nyxoah SA (NASDAQ:NYXH), the milestone begins a new phase of evidence collection following Genio's August 2025 FDA approval. The co-primary effectiveness endpoints are apnea-hypopnea-index and oxygen-desaturation-index responder rates at 12 months. Device- and procedure-related serious adverse events will be **** sed at 12 months and annually thereafter. The investment question is whether that evidence can help turn clinical credibility into sustained commercial adoption.
Nyxoah SA (NASDAQ:NYXH) has an opportunity to demonstrate how Genio performs across different physicians and treatment settings. Consistent outcomes across participating centers could give referring sleep physicians and implanting surgeons greater confidence in patient selection and treatment delivery.
The product offers a distinct approach. Genio stimulates hypoglossal nerves on both sides of the tongue, using a battery-free implant powered by an external wearable. For Nyxoah SA (NASDAQ:NYXH), documenting effectiveness and safety in routine practice could help physicians **** s how that design fits their patients' needs.
Longer follow-up could also strengthen the evidence available to payers. Nyxoah SA (NASDAQ:NYXH) could use sustained responses and safety findings to support coverage discussions, while participating centers gain practical experience with implantation and follow-up. That would make BREATHE valuable beyond a single headline response rate.
#nyxoah #NASDAQ #nyxh
For Nyxoah SA (NASDAQ:NYXH), the milestone begins a new phase of evidence collection following Genio's August 2025 FDA approval. The co-primary effectiveness endpoints are apnea-hypopnea-index and oxygen-desaturation-index responder rates at 12 months. Device- and procedure-related serious adverse events will be **** sed at 12 months and annually thereafter. The investment question is whether that evidence can help turn clinical credibility into sustained commercial adoption.
Nyxoah SA (NASDAQ:NYXH) has an opportunity to demonstrate how Genio performs across different physicians and treatment settings. Consistent outcomes across participating centers could give referring sleep physicians and implanting surgeons greater confidence in patient selection and treatment delivery.
The product offers a distinct approach. Genio stimulates hypoglossal nerves on both sides of the tongue, using a battery-free implant powered by an external wearable. For Nyxoah SA (NASDAQ:NYXH), documenting effectiveness and safety in routine practice could help physicians **** s how that design fits their patients' needs.
Longer follow-up could also strengthen the evidence available to payers. Nyxoah SA (NASDAQ:NYXH) could use sustained responses and safety findings to support coverage discussions, while participating centers gain practical experience with implantation and follow-up. That would make BREATHE valuable beyond a single headline response rate.
#nyxoah #NASDAQ #nyxh
5 days ago
Biohaven (BHVN) stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns.
The Food and Drug Administration is now requiring Biohaven to ***** s the potential for human toxicity from a metabolite in the drug, opakalim. Opakalim is in testing as a treatment for focal onset seizures. But, in rats, it proved toxic.
Dosing is still ongoing. But the rodent toxicity setback likely delays potential regulatory approval. That's a boon for Xenon Pharmaceuticals (XENE), which is in late-stage testing with its drug, azetukalner. Both drugs work by opening potassium channels in the nervous system to calm overactive brain cells.
On the stock market today, Biohaven stock dropped 14.7% to 12.79. Shares fell below their 21-day and 50-day moving averages on the news, MarketSurge shows. Xenon stock slid a fraction to 58.80.
To ask for FDA approval, Biohaven will need the results of studies called RISE-2 and RISE-3. The hold was placed on the former, but the latter is still ongoing. The company expects to have the results from RISE-3 later this year.
#toxicity
The Food and Drug Administration is now requiring Biohaven to ***** s the potential for human toxicity from a metabolite in the drug, opakalim. Opakalim is in testing as a treatment for focal onset seizures. But, in rats, it proved toxic.
Dosing is still ongoing. But the rodent toxicity setback likely delays potential regulatory approval. That's a boon for Xenon Pharmaceuticals (XENE), which is in late-stage testing with its drug, azetukalner. Both drugs work by opening potassium channels in the nervous system to calm overactive brain cells.
On the stock market today, Biohaven stock dropped 14.7% to 12.79. Shares fell below their 21-day and 50-day moving averages on the news, MarketSurge shows. Xenon stock slid a fraction to 58.80.
To ask for FDA approval, Biohaven will need the results of studies called RISE-2 and RISE-3. The hold was placed on the former, but the latter is still ongoing. The company expects to have the results from RISE-3 later this year.
#toxicity
5 days ago
Boston College linebacker Bodie Kahoun suffered a frightening injury during the first half of the Eagles' game against Rutgers on Friday night.
Kahoun was injured while helping make a tackle and appeared to absorb contact to the head and upper body as another Boston College defender arrived to ***** ist on the play. He remained down on the field for several minutes while members of Boston College's medical staff attended to him.
The game was temporarily halted as Kahoun received treatment. He was eventually stretchered into an ambulance that had driven onto the field. ESPN's broadcast showed him giving a thumbs-up as he was loaded into the ambulance.
REQUIRED READING: Boston College-Rutgers football honor 9/11 victims with special uniforms
Boston College led Rutgers 20-7 at halftime. The Eagles dropped their season opener against Cincinnati in Week 1 on the road, falling to the Bearcats 34-15.
#boston #rutgers #field
Kahoun was injured while helping make a tackle and appeared to absorb contact to the head and upper body as another Boston College defender arrived to ***** ist on the play. He remained down on the field for several minutes while members of Boston College's medical staff attended to him.
The game was temporarily halted as Kahoun received treatment. He was eventually stretchered into an ambulance that had driven onto the field. ESPN's broadcast showed him giving a thumbs-up as he was loaded into the ambulance.
REQUIRED READING: Boston College-Rutgers football honor 9/11 victims with special uniforms
Boston College led Rutgers 20-7 at halftime. The Eagles dropped their season opener against Cincinnati in Week 1 on the road, falling to the Bearcats 34-15.
#boston #rutgers #field
5 days ago
Durham, North Carolina-based IQVIA Holdings Inc. (IQV) provides healthcare research services. Valued at $42.3 billion by market cap, the company offers ******* ytics, technology solutions, and clinical research services to the life sciences industry which helps them in the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients.
Companies worth $10 billion or more are generally described as "large-cap stocks," and IQV perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the diagnostics & research industry. With strong revenue growth and a global presence in over 100 countries, IQVIA's expertise and scale provide a competitive edge that is hard to replicate.
'Not Tens Of Billions, But Tens Of Trillions': Nvidia CEO Jensen Huang Says AI Is Like the New Electricity and the Scale Is Unlike Any Tech in History
What It Means for MSFT Stock Investors as Microsoft Switches to 2 Business Segments
RKLB Stock Jumps as Rocket Lab Debuts New Solar Cell for ******* e
#Research #Stock #healthcare
Companies worth $10 billion or more are generally described as "large-cap stocks," and IQV perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the diagnostics & research industry. With strong revenue growth and a global presence in over 100 countries, IQVIA's expertise and scale provide a competitive edge that is hard to replicate.
'Not Tens Of Billions, But Tens Of Trillions': Nvidia CEO Jensen Huang Says AI Is Like the New Electricity and the Scale Is Unlike Any Tech in History
What It Means for MSFT Stock Investors as Microsoft Switches to 2 Business Segments
RKLB Stock Jumps as Rocket Lab Debuts New Solar Cell for ******* e
#Research #Stock #healthcare
5 days ago
On September 11, Kate Middleton made her first solo engagement since her summer break, visiting The Royal Marsden Hospital in London, where she received cancer treatment in 2024.
The Princess of Wales said that she was "really, really grateful on a personal level" for her treatment there.
For the occasion, the future queen rewore an apple green Suzannah London dress that she owns in multiple colors.
For a poignant visit to the hospital where she received cancer treatment throughout 2024, Kate Middleton chose another vibrant pop of color—this time, apple green.
On September 11, the Princess of Wales visited The Royal Marsden Hospital, which she supported earlier this summer through her grueling Three Peaks Challenge. The trek saw the future queen climb the highest mountains in Scotland, England, and Wales in under 24 hours, and in doing so, the princess raised money for the London hospital.
#hospital #middleton #royal #marsden
The Princess of Wales said that she was "really, really grateful on a personal level" for her treatment there.
For the occasion, the future queen rewore an apple green Suzannah London dress that she owns in multiple colors.
For a poignant visit to the hospital where she received cancer treatment throughout 2024, Kate Middleton chose another vibrant pop of color—this time, apple green.
On September 11, the Princess of Wales visited The Royal Marsden Hospital, which she supported earlier this summer through her grueling Three Peaks Challenge. The trek saw the future queen climb the highest mountains in Scotland, England, and Wales in under 24 hours, and in doing so, the princess raised money for the London hospital.
#hospital #middleton #royal #marsden
5 days ago
Princess Kate made a deeply meaningful jewelry choice as she joined Prince William for a surprise appearance in Liverpool on Thursday.
You may also like
Prince Harry's first UK engagements revealed: Will Meghan Markle be by his side?
Kate Middleton returns to hospital where she received cancer treatment in elegant green dress
Princess Eugenie shares emotional reunion in first appearance since welcoming baby Adelaide
#kate #prince #Liverpool
You may also like
Prince Harry's first UK engagements revealed: Will Meghan Markle be by his side?
Kate Middleton returns to hospital where she received cancer treatment in elegant green dress
Princess Eugenie shares emotional reunion in first appearance since welcoming baby Adelaide
#kate #prince #Liverpool
5 days ago
Prince Harry is preparing to step back into the public eye in the United Kingdom following his return with Meghan Markle and their two children.
You may also like
Meghan Markle revealed what she really wants to be called amid her new life in the U.K.
Kate Middleton returns to hospital where she received cancer treatment in elegant green dress
Princess Eugenie shares emotional reunion in first appearance since welcoming baby Adelaide
#kingdom
You may also like
Meghan Markle revealed what she really wants to be called amid her new life in the U.K.
Kate Middleton returns to hospital where she received cancer treatment in elegant green dress
Princess Eugenie shares emotional reunion in first appearance since welcoming baby Adelaide
#kingdom
5 days ago
The Princess of Wales looked as fresh, fabulous, and fashionable as ever on Friday morning as she arrived at the Royal Marsden Hospital in London.
Kate returned to the place where she received treatment and learned first-hand how funds raised through her National Three Peaks Challenge and ongoing support will transform holistic care for cancer patients across the UK.
Kate chose a stunning dress by Suzannah London (@ David Cliff / Kensington Palace)
The mother-of-three chose a trending colour for autumn - apple-green - in the form of a chic dress by Suzannah London. The beautiful design featured short sleeves, a subtle portrait neckline, **** on-down detailing, and an elegant front split.
The royal's dress is known as the 'Flippy Wiggle' and she has worn it once before (@ David Cliff / Kensington Palace)
#london #dress #kate #david
Kate returned to the place where she received treatment and learned first-hand how funds raised through her National Three Peaks Challenge and ongoing support will transform holistic care for cancer patients across the UK.
Kate chose a stunning dress by Suzannah London (@ David Cliff / Kensington Palace)
The mother-of-three chose a trending colour for autumn - apple-green - in the form of a chic dress by Suzannah London. The beautiful design featured short sleeves, a subtle portrait neckline, **** on-down detailing, and an elegant front split.
The royal's dress is known as the 'Flippy Wiggle' and she has worn it once before (@ David Cliff / Kensington Palace)
#london #dress #kate #david
6 days ago
The pharmaceutical sector was hit with major pipeline news on September 1 when Novartis AG (NYSE:NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy targeting autoimmune and neurological disorders. The suspension, effective August 24, followed three patient deaths caused by severe, life-threatening immune reactions (immune effector cell-associated hemophagocytic syndrome). Novartis is currently conducting a safety review alongside independent monitoring boards. Following the news, Bristol-Myers Squibb Company (NYSE:BMY) voluntarily paused trials for its competing CAR-T treatment, zola-cel, as a precautionary measure after detecting transient inflammatory side effects.
Looking at Q2 2026 earnings, Bristol Myers Squibb is currently demonstrating stronger financial momentum. Bristol-Myers Squibb Company (NYSE:BMY) reported total revenue of $13.0 billion, up 6% year over year, driven by a 15% increase in its Growth Portfolio to $7.6 billion, led by Opdivo, Qvantig, Reblozyl, and Camzyos. Non-GAAP EPS reached $2.04, while net income totaled $3.3 billion, or $4.2 billion on a non-GAAP basis. The company also raised its full-year 2026 revenue guidance from approximately $46.0–$47.5 billion to $49.0–$50.0 billion and increased its non-GAAP EPS outlook to $6.75–$7.00.
Novartis AG (NYSE:NVS), meanwhile, reported Q2 net sales of $14.4 billion, up 3% in U.S. dollars and 1% at constant currencies, supported by Kisqali and Kesimpta, which grew 43% and 32% at constant currencies, respectively. However, generic competition reduced growth by 14 percentage points, while core operating income remained flat at $5.9 billion and GAAP net income fell 19% to $3.3 billion. Novartis reaffirmed rather than raised its full-year guidance, calling for low single-digit sales growth and a low single-digit decline in core operating income.
Overall, Bristol Myers stands out as the stronger financial story this quarter, with its Growth Portfolio offsetting legacy patent-cliff pressures and supporting a guidance increase, while Novartis continues to contend with generic erosion weighing on earnings.
Novartis' bull case rests on strong double-digit growth from high-margin blockbusters such as Kisqali, Kesimpta, and Scemblix, supporting robust Q2 free cash flow of $5.6 billion. However, CAR-T safety setbacks could threaten a key pipeline platform, while intense generic competition has already reduced top-line growth by 14 percentage points.
#billion #novartis
Looking at Q2 2026 earnings, Bristol Myers Squibb is currently demonstrating stronger financial momentum. Bristol-Myers Squibb Company (NYSE:BMY) reported total revenue of $13.0 billion, up 6% year over year, driven by a 15% increase in its Growth Portfolio to $7.6 billion, led by Opdivo, Qvantig, Reblozyl, and Camzyos. Non-GAAP EPS reached $2.04, while net income totaled $3.3 billion, or $4.2 billion on a non-GAAP basis. The company also raised its full-year 2026 revenue guidance from approximately $46.0–$47.5 billion to $49.0–$50.0 billion and increased its non-GAAP EPS outlook to $6.75–$7.00.
Novartis AG (NYSE:NVS), meanwhile, reported Q2 net sales of $14.4 billion, up 3% in U.S. dollars and 1% at constant currencies, supported by Kisqali and Kesimpta, which grew 43% and 32% at constant currencies, respectively. However, generic competition reduced growth by 14 percentage points, while core operating income remained flat at $5.9 billion and GAAP net income fell 19% to $3.3 billion. Novartis reaffirmed rather than raised its full-year guidance, calling for low single-digit sales growth and a low single-digit decline in core operating income.
Overall, Bristol Myers stands out as the stronger financial story this quarter, with its Growth Portfolio offsetting legacy patent-cliff pressures and supporting a guidance increase, while Novartis continues to contend with generic erosion weighing on earnings.
Novartis' bull case rests on strong double-digit growth from high-margin blockbusters such as Kisqali, Kesimpta, and Scemblix, supporting robust Q2 free cash flow of $5.6 billion. However, CAR-T safety setbacks could threaten a key pipeline platform, while intense generic competition has already reduced top-line growth by 14 percentage points.
#billion #novartis
6 days ago
Our **** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Performance was anchored by municipal demand, which remains stable due to the non-discretionary nature of aging water infrastructure repair and evolving regulatory requirements.
Data center development has emerged as a significant growth engine, nearly doubling year-over-year, while treatment plant projects have grown to a mid-single-digit percentage of the total sales mix.
Treatment plant solutions delivered double-digit growth as the company successfully pivots toward higher-value specialty products and technical project support.
Fire protection strength was driven by a combination of market share gains in new geographies and favorable steel pricing dynamics.
#year #tell #FIRE
Performance was anchored by municipal demand, which remains stable due to the non-discretionary nature of aging water infrastructure repair and evolving regulatory requirements.
Data center development has emerged as a significant growth engine, nearly doubling year-over-year, while treatment plant projects have grown to a mid-single-digit percentage of the total sales mix.
Treatment plant solutions delivered double-digit growth as the company successfully pivots toward higher-value specialty products and technical project support.
Fire protection strength was driven by a combination of market share gains in new geographies and favorable steel pricing dynamics.
#year #tell #FIRE
6 days ago
A North Carolina mother speaks out after her family was exposed to rabid goats from a local petting zoo. This comes as state health officials recommend over 250 people seek treatment. NBC News' Anne Thompson reports.
#mother #family #exposed
#mother #family #exposed
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
6 days ago
It really just feels like each series the Atlanta Braves have been in lately has been like them leaving a snake pit for a lion's den only to realize that they've stepped into a piranha's pond and escaped that just to find out that the dry land was quicksand. "I don't know how much more battle-tested we need to be," quipped Walt Weiss when he was asked by the media during Tuesday's pregame press conference about the tough schedule that the Braves have been dealing with as of late — and still have to navigate going forward.
Indeed, one of the takeaways from this patch is that the Braves will have faced some of the toughest teams that baseball currently has to offer once they eventually reach the Postseason and they should be more-than-ready to handle whatever's in front of them. With that being said, the Braves had to deal with another serious test in the form of the Tampa Bay Rays and once the smoke cleared, it was less about acing the test and more like simply doing enough to pass the test. Did Atlanta manage that? Let's get into it.
This one was competitive for two innings, as the Braves matched Junior Caminero's two-out dinger off of AJ Smith-Shawver in the first inning with a run of their own in the bottom half of that frame. The deadlock didn't last long at all, as the Rays made the third inning a long one for Smith-Shawver. AJSS was one out away from potentially putting two outs on the board against the Rays in that inning. Instead, Liam Hicks sent one flying into the Georgia night sky for a two-run shot. Smith-Shawver was one out away from keeping it at 3-1 before Victor Mesa Jr. hit a bouncer that eluded the glove of Ozzie Albies and dribbled into the infield for an RBI single that made it 4-1.
AJ Smith-Shawver was only able to make it through 3.1 innings with those four runs allowed, but credit is due to Brent Suter for going 3.2 innings while only giving up a single run while he was out there. Elieser Hernández wasn't as fortunate, as he surrendered two runs across his two innings of work and then got the DFA treatment once the next morning rolled around. It really felt like the Rays were either ****** ing and dunking or hitting moonshots, there was no in-between in this one.
Meanwhile, a nasty trend for the Braves was emerging while they were on the mound. It's not particularly shocking that Freddy Peralta ended up going six innings with just one run allowed since he'd done pretty well in two previous starts against Atlanta with the Mets. It wasn't shocking either to see the Rays bullpen clamp down on the Braves they did on Tuesday, either. What was shocking is that the Braves came out of this game with 11 batted ****** that were at least 95-mph that ended up turning into outs. Folks, that's tough!
#Braves #smith #shawver #going
Indeed, one of the takeaways from this patch is that the Braves will have faced some of the toughest teams that baseball currently has to offer once they eventually reach the Postseason and they should be more-than-ready to handle whatever's in front of them. With that being said, the Braves had to deal with another serious test in the form of the Tampa Bay Rays and once the smoke cleared, it was less about acing the test and more like simply doing enough to pass the test. Did Atlanta manage that? Let's get into it.
This one was competitive for two innings, as the Braves matched Junior Caminero's two-out dinger off of AJ Smith-Shawver in the first inning with a run of their own in the bottom half of that frame. The deadlock didn't last long at all, as the Rays made the third inning a long one for Smith-Shawver. AJSS was one out away from potentially putting two outs on the board against the Rays in that inning. Instead, Liam Hicks sent one flying into the Georgia night sky for a two-run shot. Smith-Shawver was one out away from keeping it at 3-1 before Victor Mesa Jr. hit a bouncer that eluded the glove of Ozzie Albies and dribbled into the infield for an RBI single that made it 4-1.
AJ Smith-Shawver was only able to make it through 3.1 innings with those four runs allowed, but credit is due to Brent Suter for going 3.2 innings while only giving up a single run while he was out there. Elieser Hernández wasn't as fortunate, as he surrendered two runs across his two innings of work and then got the DFA treatment once the next morning rolled around. It really felt like the Rays were either ****** ing and dunking or hitting moonshots, there was no in-between in this one.
Meanwhile, a nasty trend for the Braves was emerging while they were on the mound. It's not particularly shocking that Freddy Peralta ended up going six innings with just one run allowed since he'd done pretty well in two previous starts against Atlanta with the Mets. It wasn't shocking either to see the Rays bullpen clamp down on the Braves they did on Tuesday, either. What was shocking is that the Braves came out of this game with 11 batted ****** that were at least 95-mph that ended up turning into outs. Folks, that's tough!
#Braves #smith #shawver #going
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
6 days ago
Eminem's ex-wife Kim Mathers is reportedly not behind bars and is now in treatment amid her legal troubles.
On Thursday, September 10, The U.S. Sun reported that Kim, 51 — who has struggled with substance abuse over the years — was released from jail in Michigan as the Macomb County Prosecutor's Office confirmed she "is no longer in custody at the Macomb County Jail."
A jail spokesperson told the outlet she was only behind bars for a few days and was most likely released because she secured a spot for treatment.
Kim appeared in court on August 13, when the judge said he was revoking her bond, as seen in a video of the hearing posted on YouTube.
Macomb County Prosecutor's Office
#county #treatment
On Thursday, September 10, The U.S. Sun reported that Kim, 51 — who has struggled with substance abuse over the years — was released from jail in Michigan as the Macomb County Prosecutor's Office confirmed she "is no longer in custody at the Macomb County Jail."
A jail spokesperson told the outlet she was only behind bars for a few days and was most likely released because she secured a spot for treatment.
Kim appeared in court on August 13, when the judge said he was revoking her bond, as seen in a video of the hearing posted on YouTube.
Macomb County Prosecutor's Office
#county #treatment
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
